The Prenatal Diagnosis of Neural Tube and Other Congenital Defects

Milunsky, Aubrey

doi:10.1007/978-1-4684-5155-9_16

Cited by 16 publications

(6 citation statements)

References 318 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ülkemizde her yıl yaklaĢık 5000 çocuk NTD ile doğmaktadır (Tunçbilek ve ark., 1999). Ġngiltere'nin kuzey ve batı bölgelerinde yüksek insidans (% 0,8) görülürken, güney ve doğusunda düĢük insidans (% 0,2 -% 0,3) görülmektedir (Milunsky, 1986). Amerika ve Kanada'da insidans oldukça düĢüktür (% 0,1).…”

Section: Gġrġġunclassified

Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo Model

KAYA

Akalan

Türkmenoğlu

2022

Kocatepe Veterinary Journal

View full text Add to dashboard Cite

Bu çalışmada tip 2 diyabet ve obezite tedavisinde kullanılan inkretin bazlı glukagon benzeri peptid-1 (GLP-1) reseptör agonistlerinden liraglutid’in civciv embriyo modelinde nöral tüp üzerine etkilerinin incelenmesi amaçlandı. Çalışmada 100 adet 61 ± 5 gr ağırlıkta, spesifik patojen içermeyen yumurta 37.5 ± 0.5°C’de ve % 60 - 68 nem ortamında 28 saat inkübe edildi. Bu süre sonunda pencerleme tekniği ile açılan yumurtalar 4 gruba (n=25) ayrılarak subblastodermik olarak uygulama yapıldı. Kontrol grubuna % 0.9 steril serum fizyolojik, deney gruplarına ise 1.5 µg, 7.5 µg ve 15 µg dozda liraglutid enjekte edildi. Enjeksiyon sonrası pencereler steril drape ile kapatılarak inkübasyona bırakıldı. 48 saat inkübasyon sonunda tüm yumurtalar açılıp Hamburger-Hamilton skalası temel alınarak değerlendirildi. Çalışmada nöral tüp açıklığı, somit sayıları, Hamburger Hamilton evreleri incelenmesinde kontrol grubu ile deney grupları arasındaki doza bağlı farkın istatistiksel olarak anlamlı olmadığı tespit edildi (p>0.05). Baş-kıç uzunlukları bakımından yüksek doz grubu ile diğer gruplar arasındaki farkın istatistiksel olarak anlamlı olduğu tespit edildi (P

show abstract

Section: Gġrġġunclassified

Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo Model

KAYA

Akalan

Türkmenoğlu

2022

Kocatepe Veterinary Journal

View full text Add to dashboard Cite

show abstract

“…However, while CVS might reassure parents that their child does not have certain chromosomal and genetic disorders, one disadvantage of CVS is that, unlike amniocentesis, it cannot be used to diagnose neural tube defects (NTDs) such as spina bifida and anencephaly. Although the majority of debilitating congenital disorders are the result of chromosomal and genetic anomalies, most of which can be detected by CVS, the incidence rate for NTDs is still significant at between 1.0 and 1.6 per 1,000 birthsabout the same as for Down syndrome, the most common major chromosomal disorder in newborns (32,33). Also, unlike genetic disorders which are generally inherited, 95 per cent of all infants with NTDs are born to parents with no previous family history of the disorder (32).…”

Section: Higher Rate Of 'Unnecessary' Selective Abortionsmentioning

confidence: 99%

First trimester prenatal diagnosis: earlier is not necessarily better.

Boss

1994

J Med Ethics

View full text Add to dashboard Cite

In the past few years considerable attention has been given to a relatively new method of prenatal diagnosis known as chorionic villus sampling (CVS). Because CVS can be performed in the first trimester it is hailed by many as a significant advance over amniocentesis. What has not been as publicized, however, are the disadvantages of CVS and earlier prenatal diagnosis. The emotional costs of CVS in terms of the greater number of both spontaneous and selective abortions following CVS, the use of CVS for sex selection and, because of the greater social acceptability of first trimester abortion, the possibility of increased pressure on women to undergo prenatal diagnosis by health insurance companies, medical professionals and government agencies, all need to be weighed against the advantages of early prenatal diagnosis.

show abstract

“…Maternal serum alpha-fetoprotein screening is widely offered to pregnant women for the detection of fetal neural tube defects (NTD). Elevated values are associated not only with open fetal lesions but also with a variety of other pregnancy complications (Milunsky, 1986). Case reports of fetal triploidy detected in the course of MSAFP screening indicate that this abnormal fetal condition must be considered when MSAFP is elevated.…”

Section: Introductionmentioning

confidence: 99%

Prenatal ascertainment of triploidy by maternal serum alpha‐fetoprotein screening

et al. 1989

View full text Add to dashboard Cite

We report our experience in ascertaining fetal triploidy during routine maternal serum alpha-fetoprotein (MSAFP) screening. Three cases were identified after elevated MSAFP tests. Two of the three had normal amniotic fluid alpha-fetoprotein (AFAFP). The third had amniocentesis too late for AFAFP interpretation. Three additional cases were detected by amniocentesis without prior MSAFP screening and none had an elevated AFAFP. A literature review revealed eight triploid fetuses detected as a result of an elevated MSAFP. Of the five with AFAFP quantitation, only one had an abnormal value and the elevation was minimal. In these 14 cases from our own and other reports, ultrasound findings of placental and fetal abnormalities were often noted, but a pattern diagnostic of triploidy was not present. We conclude that, for optimal prenatal detection of triploidy, fetal karyotyping should be included when an amniocentesis is performed for elevated MSAFP.

show abstract

The Prenatal Diagnosis of Neural Tube and Other Congenital Defects

Cited by 16 publications

References 318 publications

Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo Model

Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo Model

First trimester prenatal diagnosis: earlier is not necessarily better.

Prenatal ascertainment of triploidy by maternal serum alpha‐fetoprotein screening

Contact Info

Product

Resources

About